97307 ⎘
Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Amyloid-beta binding proteins
#10202Cross-reactive antibodies against dengue virus and uses thereof
#10203Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#10204Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor
#10205Anti-antibodies and methods of use
#10206ADAM6 mice
#10207Antibody specific to , therapeutic method and detection method using same
#10208Antibody molecules to PD-1 and uses thereof
#10209Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same
#10210Enhancement of transport of therapeutic molecules across the blood brain barrier
#10211Antibody specifically binding to ANG2 and use thereof
#10212Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
#10213Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#10214Anti-CD38 antibodies
#10215Anti IL-36R antibodies
#10216DAC HYP compositions and methods
#10217Human antibodies to PD-L1
#10218Human antibodies to PD-1
#10219Anti-Siglec-8 antibodies and methods of use thereof
#10220Mouse FcγammaRII-specific Fc antibody
#10221ANTIBODIES TO IL-6 AND THEIR USES
#10222α/β-peptide mimics of Z-domain peptides
#10223Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#10224ENDOGLIN PEPTIDES TO TREAT FIBROTIC DISEASES
#10225ADAM6 mice
#10226DAC HYP compositions and methods
#10227Compounds
#10228Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19
#10229Anti-ANGPTL3 antibodies and uses thereof
#10230Anti-plasmodium parasite antibodies
#10231Jagged-binding agents and uses thereof
#10232Antibodies that neutralize botulinum neurotoxins
#10233BINDING MOIETIES FOR BIOFILM REMEDIATION
#10234Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#10235Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#10236Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#10237HUMAN ANTI-KIR ANTIBODIES
#10238Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
#10239Mica binding agents
#10240Alpha-enolase specific antibodies and methods of uses in cancer therapy
#10241Compositions and methods for diagnosing and treating cancer
#10242Engineered immunoglobulin FC polypeptides
#10243Antagonist antibodies against EphB3
#10244Antibodies against the RGM a protein and uses thereof
#10245Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies
#10246Polynucleotides encoding IL-31 monoclonal antibodies
#10247Method of treating pruritus with IL-31 monoclonal antibodies
#10248DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#10249CRYSTALLINE ANTI-HTNFALPHA ANTIBODIES
#10250Methods of treating complement-associated disorders with anti-C5a antibodies
#10251Monoclonal antibody binding specifically to DLL4 and use thereof
#10252Antibodies to tau
#10253Monoclonal antibody against D-dimer and methods of use therefor
#10254Alpha-enolase specific antibodies and method of use in immune diseases
#10255Multifunctional antibodies binding to EGFR and MET
#10256Dimeric protein with triple mutations
#10257PRLR-SPECIFIC ANTIBODY AND USES THEREOF
#10258OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
#10259Deimmunized serum-binding domains and their use in extending serum half-life
#10260Nucleic acids encoding antibodies against human CSF-1R and uses thereof
#10261Anti-IL-17A antibodies and their uses
#10262Humanized anti-Tau(pS422) antibodies and methods of use
#10263Humanized tau antibody
#10264ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE
#10265Stayed roller furler
#10266Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
#10267Antibodies and immunoconjugates and uses therefor
#10268Antibodies and conjugates that target misfolded prion protein
#10269Methods of reducing IL-6 activity for disease treatment
#10270Cytotoxic immunoglobulin
#10271Anti-CD3 antibodies and methods of use
#10272Compositions and methods for treating fatty tissue buildup
#10273ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE
#10274Humaneered anti-factor B antibody
#10275Anti-HSV antibody
#10276Antibody-binding protein-drug conjugate and methods of use
#10277Antibodies against human CSF-1R and uses thereof
#10278Compositions comprising antibodies targeting factor P
#10279Carrier for antibody purification, manufacturing method for same, and application for same
#10280Dual receptor antagonistic antigen-binding proteins and uses thereof
#10281Anti-C-Met/anti-Ang2 bispecific antibody
#10282Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
#10283IL-17 antagonistic antibodies
#10284Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2
#10285Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8
#10286Bispecific HIV-1 neutralizing antibodies
#10287Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies
#10288Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
#10289Crystalline anti-human IL-23p19 antibodies
#10290Methods of treating moderate to severe hidradenitis suppurativa with anti-TNFalpha antibody
#10291High-affinity monoclonal antibodies to glypican-3 and use thereof
#10292Caninized anti-NGF antibodies and methods thereof
#10293CD33 antibodies and use of same to treat cancer
#10294ANTIBODIES AGAINST HGF - RECEPTOR AND USES
#10295Anti-αβantibodies
#10296Method of detecting human matrix metalloproteinase 9 using antibodies
#10297Therapeutic biologic for treatment of hepatocellular carcinoma
#10298Method of combination therapy using an anti-C-Met antibody
#10299IL-6 binding molecules
#10300TLR3 binding agents
#10301Human monoclonal antibody
#10302Compositions and methods for treating IgE-mediated disorders
#10303Active protease-resistant antibody FC mutants
#10304Anti-Siglec-15 antibodies
#10305Neo antibodies for diagnostic imaging of tissue injury
#10306Production of T cell retargeting hetero-dimeric immunoglobulins
#10307Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
#10308Bispecific antibodies against human TWEAK and human IL17 and uses thereof
#10309Human bispecific EGFRvIII antibody and CD3 engaging molecules
#10310Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
#10311Anti-human IL-23 receptor antibody and encoding polynucleotides
#10312Compositions relating to a mutant toxin and methods thereof
#10313Antibodies against CD106 (VCAM-1)
#10314IL-6 antagonists and uses thereof
#10315Anti-CCL17 antibodies
#10316Antibodies directed to angiopoietin-2 and uses thereof
#10317Monoclonal canine CD20 antibodies and methods of use
#10318Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#10319Humanized anti-IL-20 antibody and uses thereof
#10320Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#10321Anti-FcRn antibodies
#10322Anti-c-met antibodies
#10323ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES
#10324Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
#10325Antibodies directed against nerve growth factor (NGF)
#10326Dabigatran antidotes
#10327Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
#10328Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
#10329Class I anti-CEA antibodies and uses thereof
#10330TNF-ALPHA BINDING PROTEINS
#10331Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer
#10332Anti-human folate receptor beta antibodies and methods of use
#10333Biological materials related to CXCR7
#10334Anti-Human Cytomegalovirus Antibodies And Use Thereof
#10335Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient
#10336Anti-transferrin receptor antibodies and methods of use
#10337Bispecific scFv immunofusion (BIf)
#10338Antibodies or antigen-binding fragments thereof specifically binding to VEGF-C and use thereof
#10339Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same
#10340Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
#10341Antibodies that recognize IAPP
#10342Antibodies that recognize IAPP
#10343IP-10 antibodies and their uses
#10344Cysteine engineered fibronectin type III domain binding molecules
#10345IL-17 antagonist antibodies
#10346Anti-ErbB2 antibody variants
#10347Anti-αβTCR antibody
#10348Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies
#10349VEGF binding antibodies
#10350Anti-ROBO4 antibody
#10351Antagonist antibodies and their fab fragments against GPVI and uses thereof
#10352Human antibody specific for IL-1alpha
#10353Antibodies for oncogenic strains of HPV and methods of their use
#10354Humanized and chimeric anti-factor Bb antibodies and uses thereof
#10355Monoclonal antibodies for detection of folate receptor 1
#10356Compositions and methods for treating IgE-mediated disorders
#10357Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
#10358LIGAND
#10359Human Autotaxin Antibodies and Methods of Use
#10360Anti-VEGF antibodies
#10361Anti-sPLA2-IIA antibodies and uses thereof
#10362Methods of using an alpha-4-beta-7 heterodimer specific antagonist antibody
#10363Anti-CD22 antibodies
#10364IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
#10365Cross-reactive antibody
#10366Humanized pan-HER antibody compositions
#10367Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
#10368HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME
#10369Use of an anti-Ang2 antibody
#10370Anti-PD1 antibodies and their use as therapeutics and diagnostics
#10371Methods for binding members of interleukin-4 receptor α (IL-4Rα)
#10372Multispecific antibodies, multispecific activatable antibodies and methods of using the same
#10373Anti-CD11A Antibodies and Uses Thereof
#10374Hyperglycosylated binding polypeptides
#10375Single domain antibodies capable of modulating BACE activity
#10376Anti-NKG2A antibodies and uses thereof
#10377Engineered antibody for inhibition of fibrosis
#10378MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
#10379Anti-mesothelin antibodies and immunoconjugates
#10380Humanized anti-factor C3b antibodies and uses thereof
#10381Antigen binding proteins to Oncostatin M (OSM)
#10382Antibodies to tumor endothelial marker 7R
#10383Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
#10384THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
#10385Thrombin/plasmin-regulated antibodies that bind TFPI
#10386Methods for making fully human bispecific antibodies using a common light chain
#10387Reagents and methods for detecting a polymorphic protein
#10388Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#10389Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#10390Anti-ADAMTS-5 antibody, derivatives and uses thereof
#10391CDR-modified anti-Siglec-15 antibody
#10392JCV neutralizing antibodies
#10393Therapeutic canine immunoglobulins and methods of using same
#10394Nucleic acids encoding human antibodies to sialyl-lewis
#10395Antibodies that specifically bind to DRG11-responsive (dragon) proteins
#10396Antibodies that specifically bind to DRG11-responsive (dragon) proteins
#10397Fibronectin binding domains with reduced immunogenicity
#10398Anti-CXCL13 antibodies and methods of using the same
#10399Anti-NGF antibodies and methods using same
#10400Methods of treating a tauopathy
#10401SOLUBLE HUMAN M-CSF RECEPTOR AND USES THEREOF
#10402High affinity antibodies that neutralize enterotoxin B
#10403JCV neutralizing antibodies
#10404Antibodies to kallidin and des-Arg-kallidin
#10405ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES
#10406Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
#10407Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#10408Human antibodies that bind human TNF-alpha and methods of preparing the same
#10409Carrier immunoglobulins
#10410Carrier immunoglobulins
#10411Therapeutic Antibodies
#10412Anti-phospholipase D4 antibody
#10413Bispecific antibodies which bind EGFR and VEGF
#10414Pseudomonas aeruginosa PCRV binding single variable domain antibodies
#10415Antibodies that specifically bind to the EphA2 receptor
#10416Animal models and therapeutic molecules
#10417Antibody against affinity complex
#10418HA binding agents
#10419Anti-tumor necrosis factor-alpha agents and uses thereof
#10420Angiopoietin-2 specific antibodies and uses thereof
#10421Antigen binding protein and its use as addressing product for the treatment of cancer
#10422Anti-Activin A antibodies and uses thereof
#10423Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6R
#10424Anti-CXCR4 antibodies and antibody-drug conjugates
#10425Methods of inhibiting solid tumor growth by administering GPR49 antibodies
#10426Methods and compositions for inhibiting CD32B expressing cells
#10427Methods and compositions for inhibiting CD32b expressing cells
#10428IL-1β neutralizing human monoclonal antibodies
#10429ACTRIIB BINDING AGENTS AND USES THEREOF
#10430Method of blocking vascular leakage using an anti-ANG2 antibody
#10431Anti-Ang2 antibody
#10432Antibodies for botulinum neurotoxins
#10433Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same
#10434Bispecific chimeric proteins comprising DARPins
#10435Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient
#10436Meditopes and meditope-binding antibodies and uses thereof
#10437COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES
#10438ANTI MIF ANTIBODIES
#10439Antibody polypeptides that antagonize CD40L
#10440Binding molecules for BCMA and CD3
#10441Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
#10442FcγRIIB-specific antibodies and methods of use thereof
#10443Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof
#10444Anti-ADDL monoclonal antibody and uses thereof
#10445ANTI-VEGF ANTIBODIES
#10446Compositions and methods for the diagnosis and treatment of tumor
#10447Single domain antibodies as inhibitors of PCSK9
#10448Anti-IGF antibodies
#10449Ang-2 specific antibodies and uses thereof
#10450Anti-RSPO2 antibodies
#10451Influenza A virus specific antibodies
#10452Anti-RSPO1 antibodies and uses thereof
#10453Human PAC1 antibodies
#10454Treatment of allergic diseases with recombinant antibodies
#10455Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
#10456Optimized Fc variants
#10457Monoclonal antibodies against CD32b
#10458Lectin-like oxidized LDL receptor 1 antibodies and methods of use
#10459Factor XII inhibitors for the treatment of neurological inflammatory disorders
#10460Anti-Bv8 antibodies and uses thereof
#10461Nucleic acids encoding anti-CXCR3 antibodies
#10462Humanized anti-CD134 (OX40) antibodies and uses thereof
#10463Anti-KDR antibodies and methods of use
#10464Lectin-like oxidized LDL receptor 1 antibodies and methods of use
#10465Anti-HER3 antibodies and uses thereof
#10466Human monoclonal antibodies broadly protective against influenza B virus and methods of using the same
#10467Optimized Fc variants and methods for their generation
#10468Method of producing 4-1BB binding molecules and associated nucleic acids
#10469Antibodies specific to pyroglutamated Aβ
#10470Anti-DLL3 antibody drug conjugates for treating cancer
#10471Antibodies cross-reactive to human and mouse c-Met and uses thereof
#10472Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
#10473Thrombin-binding antibody molecules and uses thereof
#10474METHODS FOR THE TREATMENT OF GOUT
#10475Anti-DLL3 antibody drug conjugates
#10476CYTOTOXIC IMMUNOGLOBULIN
#10477Anti-DLL3 antibodies
#10478Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
#10479Anti-DLL3 antibody drug conjugates and methods of use
#10480Anti-IL-23 antibodies
#10481Anti-LRP6 antibodies
#10482Binding molecules specific for HER3 and uses thereof
#10483Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
#10484Methods for suppressing cancer by inhibition of TMCC3
#10485Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#10486Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#10487Antibodies specific for trop-2 and their uses
#10488IMMUNOGLOBULIN FC VARIANTS
#10489IL-17 binding proteins
#10490Production of heavy chain only antibodies in transgenic mammals
#10491Erythrocyte-binding therapeutics
#10492Anti-wall teichoic antibodies and conjugates
#10493Antibodies to human GDF8
#10494Method of target membrane protein depletion
#10495Antigen binding proteins that bind PD-1
#10496Human growth hormone receptor antagonist antibodies and methods of use thereof
#10497Targeted binding agents against B7-H1
#10498Methods of treating progressive forms of multiple sclerosis comprising subcutaneously administering daclizumab
#10499Multivalent fibronectin based scaffold domain proteins
#10500Nucleic acids that encode interleukin-6 receptor binding polypeptides